Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Short term financial aid is available to those in need. Find out where to access assistance and improve your situation.
27,173 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Salesforce just delivered a solid quarter with revenue and adjusted earnings topping expectations and a $50 billion b...
A familiar theme in energy investing is volatility followed by opportunity. This nuclear energy stock has recently fa...
Three social platforms are drawing fresh attention as growth meets reasonable prices. Here’s a practical, investor-fr...
Investors woke up to a sharp move in Life360 after a strong Q4 report, but guiding headwinds sparked a sell-off. This...
BioNTech’s stock is under pressure as investors react to weak guidance and leadership pivots. This deep dive breaks d...
A middle-aged couple with a sizable traditional retirement balance confronts a looming tax spike as required withdraw...
A university dean warns that AI's push for efficiency could erase entry-level roles for young workers, even as they d...
A writer and friend test a cold plunge before a work-from-home day, reporting a sharper, calmer morning. The piece ex...
Kick off your weekend with a focused set of 10 Sunday Reads for investors. This practical briefing translates headlin...
Regencell Bioscience sits in the high-risk, high-reward world of early-stage biotech. Before you consider investing, ...
The question on many investors' minds is clear: is it too late to buy Ethereum in 2026? This article breaks down the ...